This prospective, multicenter observational study will evaluate glucose profiles using continuous glucose monitoring (CGM) in 100 adults with diabetes receiving peritoneal dialysis (PD) or planning to start PD within 3 months. The study will examine associations between CGM metrics and PD regimen, glucose-lowering treatment, conventional glycemic markers, dialysis-related measures, and clinical outcomes including glycemic emergencies, hospitalizations, cardiovascular events, and mortality over 12 months.
Stage 5 CKD patients
who have received PD for at least 3 months, OR
who are planned for PD within the next 3 months.
Age 18-80 years old
Patients who are planning to switch to hemodialysis or renal transplant in the coming 3 months
Life expectancy <6 months
Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites
HbA1c > 11% at enrolment
Adults with diabetes and stage 5 chronic kidney disease who are receiving peritoneal dialysis or are planned to initiate peritoneal dialysis within 3 months.
Cohort
Prospective
Continuous glucose monitoring system
DeviceSibionics GS3 CGM
Continuous glucose monitoring-derived metrics
CGM derived time in ranges
HbA1c
HbA1c by venous blood
24-hour dialysate and ultrafiltration volume
24-hour dialysate and ultrafiltration volume,
Residual renal function
Defined by 24-hour urine volume
Hospitalization for hyperglycemic or hypoglycemic emergencies
Incidence of hospitalization due to hyperglycemic or hypoglycemic emergencies during follow-up
Click on the lead sponsor to view all of their trials.
Elaine Chow
Lead sponsor
Chinese University of Hong Kong
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
